What is IPH6101?
IPH6101 is the first trifunctional anti-CD123 NKp46/CD16 NK cell engager using Innate’s proprietary multispecific antibody format ANKET®.
IPH6101 has shown anti-tumor activity in pre-clinical models, including supporting pharmacokinetic/pharmacodynamic (PK/PD) and safety data in non-human primate studies, leading to its selection as a drug candidate for development.
Mecanism of action
It induces a dual targeting of the NK activating receptors NKp46 and CD16, for an optimized NK cell activation, based on Innate’s ANKET® (Antibody-based NK cell Engager Therapeutics) proprietary platform.